Societal and individual burden of illness among fibromyalgia patients in France: Association between disease severity and OMERACT core domains

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Perrot, Serge ^a   Schaefer, Caroline ^b   Knight, Tyler ^b   Hufstader, Meghan ^b   Chandran, Arthi B ^c   Zlateva, Gergana ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Covance Market Access Services Inc   (United States)

^c PFIZER INC   (United States)

Author keywords

Burden of illness; Fibromyalgia; France; Healthcare costs; Outcome Measures in Rheumatology Clinical Trials (OMERACT); Quality of life

Indexed keywords

ADULT; ARTICLE; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; FEMALE; FIBROMYALGIA; FRANCE; HEALTH CARE COST; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PATIENT ATTITUDE; PATIENT SATISFACTION; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; SLEEP; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DISABILITY; ECONOMICS; HOSPITALIZATION; MEDICAL LEAVE; MIDDLE AGED; OUTCOME ASSESSMENT; PSYCHOLOGICAL ASPECT; STANDARD; VALIDATION STUDY;

ANALGESIC AGENT;

ANALGESICS; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DISABILITY EVALUATION; FEMALE; FIBROMYALGIA; FRANCE; HEALTH CARE COSTS; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SICK LEAVE;

EID: 84857020478     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-22     Document Type: Article

References (37)

1. The prevalence and characteristics of fibromyalgia in the general population. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L, Arthritis Rheum 1995 38 1 19 28 10.1002/art.1780380104 7818567
2. Comorbidity of fibromyalgia and psychiatric disorders. Arnold LM, Hudson JI, Keck PE, Auchenbach MB, Javaras KN, Hess EV, J Clin Psychiatry 2006 67 8 1219 1225 10.4088/JCP.v67n0807 16965199 (Pubitemid 44439693)
3. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Bigatti SM, Hernandez AM, Cronan TA, Rand KL, Arthritis Rheum 2008 59 7 961 967 10.1002/art.23828 18576297 (Pubitemid 351990992)
4. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL, J Occup Environ Med 2008 50 1 13 24 10.1097/JOM.0b013e31815cff4b 18188077
5. Prevalence of fibromyalgia: A large-scale European survey: Results in Germany. Späeth M, Roué-Le Lay K, Boussetta S, André E, Caubère JP, Taeb C, Ann Rheum Dis 2008 67 2 259 Abstract THU0389
6. Prevalence of fibromyalgia: Early Results in Russia. Nasonov EL, Soldatov D, Roué-Le Lay K, Boussetta S, Caubère J, Taeb C, Ann Rheum Dis 2008 67 2 259 Abstract THU0391
7. Prevalence of fibromyalgia: a survey in five European countries. Branco JC, Bannwarth B, Failde I, Abello Carbonell J, Blotman F, Spaeth M, Saraiva F, Nacci F, Thomas E, Caubere JP, et al. Semin Arthritis Rheum 2010 39 6 448 453 10.1016/j.semarthrit.2008.12.003 19250656
8. Fibromyalgia syndrome in the general population of France: a prevalence study. Bannwarth B, Blotman F, Roué-Le Lay K, Caubère JP, André E, Taeb C, Joint Bone Spine 2009 76 2 184 187 10.1016/j.jbspin. 2008.06.002 18819831
9. Fibromyalgia syndrome: a relevant recent construction of an ancient condition? Perrot S, Curr Opin Support Palliat Care 2008 2 2 122 127 10.1097/SPC.0b013e3283005479 18685409
10. Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Perrot S, Bouhassira D, Fermanian J, Pain 2010 150 2 250 256 10.1016/j.pain.2010.03.034 20488620
11. Fibromyalgia Criteria and Severity Scales for Clinical and Epidemiological Studies: A Modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Hauser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, J Rheumatol 2011 38 6 1113 1122 10.3899/jrheum.100594 21285161
12. Guideline for the management of fibromyalgia syndrome pain in adults and children. American Pain Society, APS Clinical Practice Guidelines Series 2005
13. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, Da-Silva JA, Danneskiold-Samsøe B, Dincer F, Henriksson C, et al. Ann Rheum Dis 2008 67 4 536 541 17644548 (Pubitemid 351498437)
14. Toward Development of a Fibromyalgia Responder Index and Disease Activity Score: OMERACT Module Update. Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA, Simon LS, Strand V, Williams DA, Arnold LM, J Rheumatol 2011 38 7 1487 1495 10.3899/jrheum.110277 21724721
15. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Boonen A, Van Den-Heuvel R, Van-Tubergen A, Goossens M, Severens JL, Van Der-Heijde D, Van Der-Linden S, Ann Rheum Dis 2005 64 3 396 402 15271773 (Pubitemid 40283049)
16. The impact of a diagnosis of fibromyalgia on health care resource use by primary care patients in the UK: an observational study based on clinical practice. Hughes G, Martinez C, Myon E, Taeb C, Wessely S, Arthritis Rheum 2006 54 1 177 183 10.1002/art.21545 16385513 (Pubitemid 43122200)
17. Characteristics and patterns of healthcare utilization of patients with fibromyalgia in general practitioner settings in Germany. Berger A, Sadosky A, Dukes E, Martin S, Edelsberg J, Oster G, Curr Med Res Opin 2008 24 9 2489 2499 10.1185/03007990802316550 18664319
18. Characteristics of patients with fibromyalgia in France and Germany. Perrot S, Winkelmann A, Dukes E, Xu X, Schaefer C, Ryan K, Chandran A, Sadosky A, Zlateva G, Int J Clin Pract 2010 64 8 1100 1108 10.1111/j.1742-1241.2010. 02418.x 20497264
19. The Manual Tender Point Survey. Sinclair JD, Starz TW, Turk DC, University of Pittsburgh Medical Center 2005 Available at: http://www.fmaware. org/News2eb58.html?page=NewsArticle&id=6263. Accessed May 31, 2011
20. The fibromyalgia impact questionnaire: development and validation. Burckhardt CS, Clark SR, Bennett RM, J Rheumatol 1991 18 5 728 733 1865419
21. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group, Health Policy 1990 16 3 199 208 10109801
22. Sleep measures. Hays RD, Stewart AL, Measuring Functioning and Well-being: the Medical Outcomes Study Approach Durham, NC: Duke University Press, Stewart AL, Ware JE, 1992 235 259
23. The prevalence and severity of pain in cancer. Daut RL, Cleeland CS, Cancer 1982 50 9 1913 1918 10.1002/1097-0142(19821101)50:9<1913::AID- CNCR2820500944>3.0.CO;2-R 7116316 (Pubitemid 12001596)
24. The hospital anxiety and depression scale. Zigmond AS, Snaith RP, Acta Psychiatr Scand 1983 67 6 361 370 10.1111/j.1600-0447.1983.tb09716.x 6880820 (Pubitemid 13098606)
25. Minimal clinically important difference in the fibromyalgia impact questionnaire. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB, J Rheumatol 2009 36 6 1304 1311 10.3899/jrheum.081090 19369473
26. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M, Pain 2005 115 1-2 29 36 10.1016/j.pain.2005.01.028 15836967
27. Gabapentin acts within the locus coeruleus to alleviate neuropathic pain. Hayashida K, Obata H, Nakajima K, Eisenach JC, Anesthesiology 2008 109 6 1077 1084 10.1097/ALN.0b013e31818dac9c 19034104
28. Gabapentin produces PKA-dependent pre-synaptic inhibition of GABAergic synaptic transmission in LC neurons following partial nerve injury in mice. Takasu K, Ono H, Tanabe M, J Neurochem 2008 105 3 933 942 10.1111/j.1471-4159. 2008.05212.x 18182059 (Pubitemid 351562744)
29. Spinal alpha(2)-adrenergic and muscarinic receptors and the NO release cascade mediate supraspinally produced effectiveness of gabapentin at decreasing mechanical hypersensitivity in mice after partial nerve injury. Takasu K, Honda M, Ono H, Tanabe M, Br J Pharmacol 2006 148 2 233 244 10.1038/sj.bjp.0706731 16582934 (Pubitemid 43873042)
30. Resource utilisation and health care costs in patients diagnosed with fibromyalgia in Spain. Rivera J, Rejas J, Esteve-Vives J, Vallejo MA, Clin Exp Rheumatol 2009 27 5 Suppl 56 39 S45 20074438
31. Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study. Winkelmann A, Perrot S, Schaefer C, Ryan K, Chandran A, Sadosky A, Zlateva G, Appl Health Econ Health Policy 2011 9 2 125 136 10.2165/11535250-000000000-00000 21332254
32. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. Sicras-Mainar A, Rejas J, Navarro R, Blanca M, Morcillo Á Larios R, Velasco S, Villarroya C, Arthritis Res Ther 2009 11 2 54 10.1186/ar2673 19366441
33. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in the DMC3 study. Picavet HS, Hoeymans N, Ann Rheum Dis 2004 63 6 723 729 10.1136/ard.2003.010769 15140781 (Pubitemid 38658404)
34. Chronic widespread musculoskeletal pain-a comparison of those who meet criteria for fibromyalgia and those who do not. Cöster L, Kendall S, Gerdle B, Henriksson C, Henriksson KG, Bengtsson A, European journal of pain (London, England) 2008 12 5 600 610 10.1016/j.ejpain.2007.10.001 (Pubitemid 351618415)
35. Societal and patient burden of fibromyalgia syndrome. Annemans L, Le-Lay K, Taeb C, Pharmacoeconomics 2009 27 7 547 559 10.2165/11313650-000000000-00000 19663526
36. Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. Cappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, Martin S, Sleep Med 2009 10 7 766 770 10.1016/j.sleep. 2008.09.004 19185539
37. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ, J Rheumatol 2003 30 6 1318 1325 12784409 (Pubitemid 36666360)